Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04477512 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04477512 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 18 participants.
The verdict
NCT04477512, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this study is to determine the recommended phase 2 dose of the multi-drug combination of abiraterone, cabozantinib, and nivolumab in conjunction with ongoing androgen deprivation therapy in previously untreated metastatic hormone-sensitive prostate cancer patients. The investigators hypothesize that the combination of cabozantinib and abiraterone acetate/prednisone in conjunction with nivolumab will have an acceptable safety profile and will be feasible to administer in patients with hormone-sensitive metastatic prostate cancer.
Interventions
- DRUG Nivolumab
- DRUG Prednisone
- DRUG Cabozantinib
- DRUG Abiraterone acetate
- PROCEDURE Peripheral blood collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-02-19 |
| Est. Completion | 2025-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04477512
The ClinicalTrials.gov registry entry for NCT04477512 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT04477512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04477512 about?
NCT04477512 is a clinical study titled "Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)". The goal of this study is to determine the recommended phase 2 dose of the multi-drug combination of abiraterone, cabozantinib, and nivolumab in conjunction with ongoing androgen deprivation therapy in previously untreated metastatic hormone-sensitive prostate cancer patients. The investigators hypo...
What is the current status of trial NCT04477512?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-02-19. Estimated completion is 2025-09-10.
What interventions are being tested in trial NCT04477512?
The interventions under investigation include: Nivolumab (DRUG), Prednisone (DRUG), Cabozantinib (DRUG), Abiraterone acetate (DRUG), Peripheral blood collection (PROCEDURE).
Who is sponsoring clinical trial NCT04477512?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.